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Abstract 
 
Rampant activity of the hypoxia-inducible factor HIF-1 in cancer is frequently associated with the 
malignant progression into a harder-to-treat, increasingly aggressive phenotype. Clearly, anti-HIF 
strategies in cancer cells are of considerable clinical interest. One way to fine-tune, or inhibit, HIF’s 
transcriptional outflow independently of hydroxylase activities could be through competing transcription 
factors. A CACGTG-binding activity in human hepatoma cells was previously found to restrict HIF’s 
access to hypoxia response cis-elements (HREs) in a Daphnia globin gene promoter construct (phb2). 
The CACGTG-factor, and its impact on hypoxia-responsive human genes, was analyzed in this study 
using genome-wide computational scans as well as gene specific quantitative PCR, reporter and DNA 
binding assays in hepatoma (Hep3B), cervical carcinoma (HeLa) and breast carcinoma (MCF7) cells. 
Among six basic helix-loop-helix transcription factors known to target CACGTG palindromes, we 
identified upstream stimulatory factor (USF)-1/2 as predominant phb2 CACGTG-constituents in Hep3B, 
HeLa and MCF7 cells. Human genes with adjacent or overlapping HRE and CACGTG motifs included 
with lactate dehydrogenase A (LDHA) and Bcl-2/E1B 19 kDa interacting protein 3 (BNIP3) hypoxia-
induced HIF-1 targets. Parallel recruitment of HIF-1α and USF1/2a to the respective promoter chromatin 
was verified for all cell lines investigated. Mutual complementing (LDHA) or moderating (BNIP3) 
crosstalk was seen upon over-expression or silencing of HIF-1α and USF1/2a. Distinct (LDHA) or 
overlapping (BNIP3) promoter-binding sites for HIF-1 and USFs were subsequently characterized. We 
propose that, depending on abundance or activity of its protein constituents, O2-independent USF 
signaling can function to fine-tune or interfere with HIF-mediated transcription in cancer cells. 
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Introduction 
 
Relaying minutes-to-hours of inadequate oxygenation (hypoxia) onto the level of DNA via the hypoxia 
inducible transcription factors 1 and 2 (HIF-1 and -2) is a highly conserved signaling event across the 
animal kingdom (1, 2). When exposed to low oxygen partial pressures (pO2), the mammalian HIF-1/-2 
complexes function as heterodimer of HIF-1α or -2α and HIF-1β subunits (3, 4). Whereas HIF-1β, also 
known as ARNT (aryl hydrocarbon receptor nuclear translocator), is constitutively present, the activity 
and abundance of HIF-α subunits are regulated as a function of pO2. In the presence of oxygen homologs 
of prolyl hydroxylase domain 1-3 (PHD1-3) dioxygenases catalyze the Fe (II)-dependent hydroxylation of 
two proline residues contained within the oxygen-dependent degradation (ODD) domain and the N-
terminal transactivation domain (NAD; rear proline only) of HIF-1α and -2α (5-7). Once prolyl 
hydroxylated, HIF-α subunits are captured by the von Hippel-Lindau tumor suppressor protein (VHL) 
and rapidly degraded via the ubiquitin-proteasome pathway (6, 8). A second, O2-requiring post-
translational modification of HIF-1α/-2α targets a single asparagine residue within the subunits` C-
terminal transactivation domain (CAD). It is catalyzed by asparaginyl hydroxylase called factor inhibiting 
HIF-1 (FIH-1) to prohibit HIF-α:co-activator interaction and suppress trans-activation of genes under 
high oxygen (9, 10). During hypoxia, both PHD and FIH-1 activities are progressively inhibited, leading 
to α-subunit accumulation, α:β-subunit dimerization in the nucleus and binding of the heterodimer to 
hypoxia response element (HRE) within target genes. Being members of canonical CANNTG E-box 
motifs, HREs consist of a consensus 5’-VNVBRCGTG-3’ (11) (V=not T; N=any; B=not A; R=A or G). 
To date, several hundred potential (12) and more than 70 validated (11) hypoxia-responsive and HRE-
flanked gene targets of HIF-1 have been identified. Through this transcriptional outflow, HIF-1 is able to 
reprogram cellular metabolism, growth, apoptosis, and O2 supply in response to declining pO2 (11). 
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Non-redundant roles of these hydroxylase systems in the regulation of HIF-1α/-2α activities were only 
recently unraveled when it became clear that the Michaelis constant (Km) of all three PHDs and FIH-1 
predicted a distinctly lower oxygen affinity for the former (13). Consequently, PHD1-3 hydroxylases start 
to experience, relative to FIH-1, inactivation at higher pO2 during progressing hypoxia (14). Differential 
hydroxylase activities will eventually translate into a differential regulation of HIF-1 targets. By 
combining transcriptional profiling data (15) with a numerical model of the regulatory dynamics of the 
FIH-1 and PHD oxygen sensors along a virtual oxygen gradient (16), Pouysségur and colleagues were 
able to allocate HIF-1 targets into two categories: i) FIH-1 inhibited genes, i.e. those induced by 
progressive hypoxia once the NAD and, subsequently, CAD of HIF-1α/-2α are both released from 
inhibition (e.g. CA9, PHD3, LDHA), and ii) non-FIH-1 inhibited genes, i.e. those requiring solely HIF-α 
NAD activity upon sufficient PHD inhibition while being refractory to any CAD activation (e.g. PGK1, 
GAPDH) (15, 17). This categorization predicts expression of FIH-1 inhibited genes to be altered during 
severe hypoxia, whereas moderate degrees of O2 deprivation already affect non-FIH-1 inhibited genes. 
 
Yet, as another and hydroxylase-independent layer of control, HIF’s transcriptional outflow is also prone 
to be influenced by competing transcription factors. When we previously utilized reporter constructs of 
the tripartite globin-2 gene (hb2) promoter (phb2) of the planktonic crustacean Daphnia magna in 
heterologous transfections of human cancer cells we noticed a constitutive CACGTG-binding factor 
which was able to interfere with the HIF-1-driven induction of the phb2 luciferase reporter (18). Now, we 
identify this phb2 CACGTG factor across several cancer cell lines as a complex of O2-independently 
acting upstream stimulatory factors 1 and 2 (USF1, USF2). To assess both the extent and mode 
(positive/negative) of the impact of USF-signaling on HIF’s transcriptional outflow, we implemented a 
genome-wide computational scan to identify candidate human genes that contain adjacent or overlapping 
HRE and CACGTG palindrome motifs in their up- or downstream sequences. Our results suggest the 
occurrence both of positive (promoter of lactate dehydrogenase A, LDHA: USFs complement HIF control) 
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and variably negative (promoter of Bcl-2/E1B 19 kDa interacting protein 3, BNIP3: USFs interactions 
range from moderating to competing with HIF-1) crosstalk modes when HIF-1/USF constituents were 
over-expressed or silenced. The current work, therefore, provides a proof-of-principle study for the 
oxygen-independent USF pathway to influence, and, upon strong activation or over-expression, even 
inhibit HIF/HRE-mediated gene expression in human cancer cells. 
 
 
Materials and Methods 
 
Cells, RNA and quantitative PCR (qPCR): Human hepatoma (Hep3B; ATCC HB-8064), cervical 
carcinoma (HeLa; ATCC CCL-2) and breast carcinoma cells (MCF7; ATCC HTB-22) were purchased as 
short tandem repeat (STR)-authenticated lines from the American Tissue Culture Collection (ATCC) and 
maintained in high glucose (4.5g/l) Dulbecco’s modified Eagle’s medium (DMEM) as described earlier 
(18). Normoxic cultures: 37°C, room air in water-saturated atmosphere with 5% CO2 (i.e. a pO2 = 141.6 
mmHg, [O2] = 18.6% O2). Hypoxic cultures in HERA Cell240 incubator (Heraeus) or a polymer glove 
box (Coy) – 16h exposures: 37°C, in water-saturated 1% O2/5% CO2/balance N2 atmosphere. Isolation of 
total RNA, reverse transcriptions and SYBR-Green qPCR were carried out as previously reported (19, 20). 
All primers used for qPCR are listed in Supplement Table 1, ST1. 
 
Antibodies: Mouse monoclonal anti-ATF-1 antibody (25C10G, sc-270) and rabbit polyclonal anti-USF1 
(C-20, sc-229) were purchased from Santa Cruz Biotech, INC. Rabbit polyclonal anti-USF1M, anti-
USF2F, anti-USF2G, anti-USF2Z and anti-USF2aO antibodies were kindly provided by Dr. B. Viollet 
(21). Additional antibody gifts included: a) rabbit anti human DEC1 (CW27) (22); b) rabbit anti human 
MYC (23); c) rabbit anti mouse ARNT (anti-mARNT R-1 lgG) (24); d) rabbit anti human ARNT (anti-
hARNT C34) (25); e) rabbit anti human USF full length antibody (USF FL) (26). 
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Sequence scan for HRE motif and CACGTG palindrome: We used the repeat-masked human genome 
sequence as provided by the UCSC Genome Bioinformatics Website (Version hg19, GRCh37) at 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/bigZips/chromFaMasked.tar.gz. Gene definitions and 
transcription start sites were from http://hgdownload.cse.ucsc.edu/goldenPath/hg19/database/refGene.txt.gz 
(downloaded April 09, 2010). The search for motifs, implemented as R-script, was conducted among the 
1000 base flanking region up- and downstream (= ±1000 bp) of annotated transcripts. Genes containing 
both HRE and CACGTG palindrome motifs within the ±1000 bp flanks were only considered as 
HRE/palindrome gene if the motif-motif distance ≤ 100 bp. Based on these criteria, we used the GeneGo 
MetaCore system to identify pathways where HRE/ palindrome genes are overrepresented (see Table 1). 
 
Luciferase reporter: Using genomic DNA, we amplified the promoter region around the HRE and E-box 
palindrome motifs via nested PCR (for primers, see Suppl. Table ST1). Of note, the 3’-end of any given 
amplicon always extended into the first coding exon of the respective gene. In detail, we amplified and 
cloned the following promoter regions (start/end always relative to translation start ATG codon): a) 
human 4EBP1 gene, -518/+403; b) human MC1R gene, -880/+9; c) human LDHA gene, -2617/+530; d) 
human TYR gene, -400/+108. Following TOPO-cloning of the PCR products into the pCRII-TOPO 
vector (Invitrogen), the liberated insert was ligated into pGL3-basic luciferase vector (Promega AG, 
Dübendorf, Switzerland) to generate the luciferase reporter constructs. We also obtained the 
BNIP3/pGL3-basic (-753/+3) (27) and the PHD2/pGL3-basic (-607/+3) (28) luciferase reporter vector as 
kind gifts. HIF-1α (i.e. pcDNA3.1-hHIF-1-PK tag) as well as USF (pCR3-USF1, pCR3-USF2a and 
pCR3-USF2b) expression plasmids were generously supplied by Prof. P. Maxwell (29) and Dr. B. Viollet 
(30), respectively. 
 
Electrophoretic Mobility Shift Assay (EMSA) and Pull-down assay: Isolation of nuclear protein extracts 
of Hep3B, HeLa and MCF7 cells, and analysis of in vitro protein-DNA interaction by EMSA (18) and 
pull-down assays (31), was done as previously reported. All oligonucleotide sequences used as probes for 
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either assay are shown in Supplementary Table ST1. For EMSA gel supershifts, 1.0-1.5 µl of rabbit anti-
USF1M, rabbit anti-USF2G or mouse anti-HIF-1α (mgc3) was added into the reaction (30 min, room 
temperature). Negative supershift controls included 1.5 µl pre-immune serum from the same rabbit to be 
immunized against USF1M or USF2G, as well as 1.0 µl rabbit anti-human IgG (code: 309-005-003 
Jackson Immuno Research). Regarding pull-down assays, wildtype and mutated phb2 -146 palindrome or 
-107 HRE oligonucleotides, and wildtype and mutated BNIP3 -251/-246 HRE oligonucleotides, 
biotinylated at the 5’ end and PAGE purified, were annealed into double stranded DNA and immobilized 
on streptavidin-coated magnetic beads (Dynal Biotech, Oslo, Norway) as described (31). 
 
Western blot and co-immunoprecipitation: Proteins were resolved in 10% SDS polyacrylamide gels, 
transferred onto nitrocellulose membranes (Whatman GmbH, Germany), and the membranes incubated at 
4°C overnight with the following primary antibodies diluted in 5% milk TBS-T: (a) anti-HIF1α (mgc3) 
(1:500) or (b) anti-USF1M or anti-USF2G (1:750). The signal was detected with horseradish peroxidase-
conjugated goat anti-mouse or anti-rabbit (1:5000) and luminol substrate. For Co-IP experiments, 150 µg 
nuclear protein was incubated with 20 µl mouse anti-HIF-1α or 0.75 µg anti-mARNT or 2.5 µl USF 
antiserum and subsequently rotated at 4°C overnight. The next day, 40 µl of protein G beads were added 
into the mix and incubated at 4°C for another 2.5h. The extract/antibody/bead mix was collected by 
centrifugation, the pellet boiled at 95°C in 1×SDS sample buffer for 10min and the supernatant analyzed 
by Western blot. 
 
Chromatin Immunoprecipitation (ChIP) assay: ChIP assays were performed in human Hep3B, HeLa and 
MCF7 cells after a 4h exposure to normoxic (air) or hypoxic (1% O2) atmospheres as described (32). In 
brief, genomic DNA was crosslinked with bound proteins (10 min, room temperature) using 1% 
formaldehyde in 1× phosphate-buffered saline (PBS) and sonicated in a Bioruptor UCD-200 
(Diagenode sa, Liège, Belgium) or a Sonifier cell disruptor B15 (Branson) into 500-1000 bp fragments. 
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For immunoprecipitation of the DNA:protein mix, 4.5 µl rabbit polyclonal anti-HIF-1α IgG (ab2185, 
Abcam, Cambridge, UK), 10 µl rabbit polyclonal anti-USF1M or anti-USF2G was added into the 
chromatin solution. 10 µl pre-immune rabbit antiserum and 2.5 µl rabbit anti-human IgG were used as 
negative controls. The purified DNA was amplified by PCR using the ChIP primer pairs shown in 
Supplementary Table ST1.  
 
Transient luciferase reporter transfection: Half-confluent Hep3B, HeLa and MCF7 cells were transfected 
overnight using the calcium phosphate method with different luciferase (LUC) reporter constructs and 
normalization plasmids expressing β–galactosidase. For co-transfections, 15-500ng HIF-1α plasmid 
and/or 15-100ng USF1, USF2a or USF2b plasmid were added. In each transfection, pUC18 plasmid was 
used as filler DNA for a total of 2-3µg DNA. The following day, each batch of transfected cells was split 
in two for parallel 16h normoxia (N) and hypoxia (H) exposure. After 16h N/H exposure cells were lysed 
and LUC activity was measured using a commercially available Luciferase Assay System (Promega AG) 
and a SIRIUS Luminometer (Berthold Technologies, Germany). LUC activity was normalized by β-
galactosidase activity (β-galactosidase enzyme assay kit; Promega AG) and expressed as “relative 
luciferase activity” in percent (% RLA) of the total activity of all normoxic and hypoxic reactions of a 
given assay. 
 
Transient knockdown of HIF-1α, USF1 or USF2a: For transient silencing, the specific siRNA HIF-1α 
and siRNA USF1 oligonucleotides were selected based on previous publications (33-35). All siRNA 
sequences (see Suppl. Table ST1) were synthesized by Dharmacon Research Inc. SiCONTROL non-
targeting siRNA pool #2 was used as scrambled siRNA control (Dharmacon). Half-confluent Hep3B cells 
were transfected with a total of 200nM of siRNAs using Oligofectamine™ reagent (Invitrogen). In the 
combined USF1+USF2a siRNA transfection targeting both USFs, 100nM of each siRNA were added to 
the cells.  
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Statistics: Using STATA 10.0 software (Stata™ 10.0; StataCorp, USA) we compared control-vs.-
experimental mean transcript expression levels (Fig. 3) and relative luciferase activities (RLA) for each 
reporter assay (Fig. 6) within the same oxygen category (either normoxic or hypoxic results; Figs. 3 and 6) 
or for the hypoxic/normoxic fold inductions (Fig. 3, Table 3). In accordance with prior testing for 
normality of data populations and for equal variances between samples, statistical significance (i.e. p 
value < 0.05) was calculated by i) one-way Anova/post-hoc Sidak modeling (normality/variance equality 
both maintained) or Welch-approximated t-tests in case of unequal sample variances (e.g. Fig. 6B, C; 
used symbols: ∗ ; +), and ii) non-parametric Kruskal-Wallis tests plus Wilcoxon rank-sums for pairwise 
sample comparisons when both assumptions were violated (e.g. Fig. 3 and Fig. 6A, D; used symbols: #; ¶). 
 
 
Results 
 
CACGTG palindromic E-boxes often serve as binding sites for several non-HIF basic helix-loop-helix 
(bHLH) transcription factors, including ARNT (36, 37), MYC (38, 39), USFs (21), STRA13/DEC1 (22), 
ATF-1 and CREB-1 (40). To identify the factor(s) responsible for the HIF-interfering constitutive activity 
at the -146 CACGTG element within the promoter of the hb2 gene (phb2) of Daphnia magna (18), and 
map the factor(s) occurrence across different cancer cells, we conducted an EMSA survey using normoxic 
nuclear extracts from human hepatoma (Hep3B), cervical carcinoma (HeLa) and breast carcinoma cells 
(MCF7). Since HeLa and MCF7 EMSA screens yielded compatible results, Figure 1A presents Hep3B 
data only (Fig. 1A). The protein components within the constitutive complex (cc) of the -146 phb2 
binding activity were identified using specific antibodies directed against USFs, DEC1, MYC, ARNT and 
ATF-1. Of these five factors screened by supershifts (ss), only USF1 and USF2 were recognized as main 
in vitro binding factors of the -146 phb2 palindrome (Fig. 1A, lanes 3, 5, 7, 9, 11) while all other factors 
either failed (MYC, ATF-1) binding this motif or interacted (DEC1) weakly with it (Fig. 1A, lane 15; ~5-
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10% of total pool). The preponderance of USFs as protein components in the HIF-interfering complex of 
Daphnia`s hb2 promoter prompted us to subsequently focus on this transcription factor family. Increasing 
the volume of anti-USF1M (left) and anti-USF2G (right) antiserum in the binding reaction nuclear 
extracts from normoxic (N) and hypoxic (H) Hep3B reduced the intensity of the CACGTG complex in a 
dose-dependent manner (Suppl. Fig. S1A). Binding of USF proteins to the -146 phb2 E-box was clearly 
oxygen-independent (Fig. S1A). 
 
We re-evaluated our EMSA results through independent pull-down assays of Hep3B, HeLa and MCF7 
nuclear proteins using biotinylated phb2 oligonucleotides, bound to streptavidin coated magnetic beads. 
In a representative assay with HeLa normoxic (N) and hypoxic (H) nuclear extracts (Fig. 1B+C), wildtype 
biotinylated oligonucleotides (w-bio), containing the -146 CACGTG phb2 palindrome, were able to pull 
down 43 kDa USF1 (Fig. 1B), 44 kDa USF2a and 38 kDa USF2b proteins in an oxygen-independent 
manner (Fig. 1C). In support of a specific interaction, competition assays (50× comp. lanes) or beads 
coated with -146 mutant (m-bio) E-box motifs (5’-CAATGT-3’) greatly reduced or abolished the USF 
pull-down. Similar results were obtained with extracts from Hep3B and MCF7 cells (not shown). Further 
pull-down and co-immunoprecipitation analyses verified that i) USF1/2 (CACGTG preference) and HIF-
1 complexes (TACGTG preference) display high-affinity binding to distinct elements within phb2, and ii) 
the USF-HIF interference within phb2 is DNA context dependent, since we, and others (41), could not 
detect any direct physical interaction between USFs and HIF subunits (see Suppl. Fig. S1B-E). 
 
To move beyond the Daphnia hb2 promoter as a model for occurring crosstalk among E-box complexes, 
we adopted Daphnia phb2 coordinates to conduct a genome-wide screen and enrichment analysis for 
human genes that harbor, within 1000 bases from their transcriptional frame (in up- and downstream 
direction), both a 5’-VNVBRCGTG-3’ HRE consensus motif (11) and a 5’-CACGTG-3’ palindrome with 
a motif-motif distance of ≤ 100bp. According to these criteria, our survey found multiple examples of 
known HIF targets among the list of HRE/palindrome genes including vascular endothelial growth factor 
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C (VEGFC), lactate dehydrogenase A (LDHA), phosphoglucomutase 2 (PGM2), enolase 1 (ENO1), 
transferrin (TF), eukaryotic translation initiation factor 4E binding protein 1 (4EBP1), Bcl-2/E1B 19 kDa 
interacting protein 3-like (BNIP3L) and Bcl-2–associated X protein (BAX) (an Excel file with the 
detected human HRE/palindrome candidate genes is available upon request). When we looked at the top-
scoring GeneGo pathways, whose signaling components showed a highly significant enrichment of 
HRE/palindrome genes (see Table 1), we noticed several signal transductions where USFs appear to 
impinge on hypoxia signals in a highly localized manner (e.g. insulin-regulated/cap-dependent mRNA 
translation, HIF mediated transcription and cytoskeletal or cell cycle control functions). Interestingly, 
particular focal points of HRE/palindrome gene clusters included the eIF4F checkpoint of cap-dependent 
translation control, cell surface receptors for insulin and growth factors as well as actin remodeling genes 
(see Table 1; Gene Symbols). These pathway aggregations of possibly co-regulated genes inspired the 
current study to try and provide solid proof-of-principle for a USF-based modulation of, or interference 
with, the HIF transcriptional outflow for at least some of the known targets listed above. If successful, 
future work will need to comprehensively assess USF-HIF cross-talk in cancer cells in a physiological 
context (see discussion). 
 
For initial insights on HIF/USF-convergence at DNA level we i) established those genes with a strong 
human-mouse-rat (hmr) conservation of the HRE/palindrome motifs within the aligned promoter regions 
(Table 2; Suppl. Fig. S2), and ii) examined the mRNA expression of five such hmr-conserved 
HRE/palindrome candidates by quantitative real-time PCR (qPCR) in conjunction with transient, small-
interfering RNA (siRNA)-based knockdowns of HIF-1α, USF1 and USF2a in Hep3B (see Fig. 2 for 
knockdown efficacy assessment by Western blot). Transfection with scrambled (scr) RNA did not affect 
steady state abundance of HIF-1α, USF1 and USF2a proteins (scr; compare to non-transfected (non-TF) 
cells). In contrast, exposing Hep3B cells to siRNAs specifically directed against HIF-1α (siHIF-1α), 
USF1 (siUSF1), USF2a (siUSF2a) or the combination of both USFs (siUSF1/2a) resulted in a drastically 
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diminished expression of the respective factor(s). In cells subjected to a USF1 knockdown (siUSF1), 
effects on the expression of USF2a ranged from unaltered to a slight elevation. Conversely, silencing of 
USF2a (siUSF2a) was accompanied by a strong reduction of USF1 protein level (Fig.  2, USF1 signal in 
siUSF2a). Similar to these findings, both USFs were concomitantly lost in USF2 knockout mouse models, 
suggesting USF2 to be generally required as USF1 trans-activator (42). 
 
Following transient knockdown of HIF-1 and USFs in normoxic and hypoxic Hep3B cells, changes in 
mRNA levels of the HRE/palindrome candidates LDHA, BNIP3, BNIP3L, 4EBP1 and VEGFC were 
assessed by qPCR (Fig. 3). Transcripts of BNIP3, BNIP3L, LDHA and VEGFC transcripts were all up-
regulated by 1% O2/16h exposure in Hep3B treated with scrambled RNA. The 4-5-fold hypoxic induction 
of the BNIP3 and BNIP3L mRNA levels was entirely (BNIP3) or almost entirely (BNIP3L) driven by 
HIF-1α (see siHIF-1α data). Silencing USF1 and USF2a expression, however, resulted in moderately 
(siUSF1) or significantly (siUSF2a) increased fold hypoxic inductions of BNIP3 and BNIP3L genes. The 
stronger effect on the hypoxic induction of BNIP3 and BNIP3L genes by the siUSF2a treatment could 
result from its effective double knockdown of USF1 and USF2a proteins (Fig. 2). Elevated gene activity 
of LDHA in hypoxic Hep3B was weakly attenuated following siHIF-1α treatment but not impacted by 
either USF knockdown. Expression of 4EBP1, mildly suppressed in hypoxic hepatoma cells (scr data), 
was constitutively reduced upon the knockdown of USF factors. The ~2-fold hypoxic induction of 
VEGFC mRNA (scr data) was lost upon USF siRNA treatment due to a strong increase of transcript level 
in normoxic Hep3B cells. 
 
With regard to the vividly O2 responsive BNIP3 and BNIP3L genes, we also noted that the potentiation of 
the induction in USF-silenced cells subjected to 1% O2 predominantly derived from a reduced normoxic, 
rather than strengthened hypoxic, gene activation (Fig. 3). This observation highlighted the importance of 
USF1/2a in maintaining the basal transcription of either gene in oxygenated cells. Because HIF-1 is 
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known to regulate BNIP3 activity with an unusually broad O2 response profile (15, 17), the factor could 
likely encounter USFs at the BNIP3 promoter even in sub-normoxic cells. In additional qPCR analyses 
we therefore assessed if, during episodes of moderate (3% O2) or very mild degrees of O2 scarcity (10% 
O2), HIF-1 continues to control BNIP3. We also asked if, relative to harsher hypoxia (1% O2), USFs will 
compete more potently with HIF-1 for the BNIP3 regulatory binding sites at 3% and 10% O2 (see 
discussion for further reasoning). Steady state levels of BNIP3 mRNA indeed revealed for scr-transfected 
Hep3B cells robust inductions of 3.3- and 1.6-fold in cells subjected to 16h of 3% and 10% O2, 
respectively (Table 3). Together with the profiling at 1% O2 (4.8-fold transcript induction), the exquisite 
sensitivity of the BNIP3 gene across a wide range of changes in oxygen concentrations became fully 
evident. Moreover, as silencing of HIF-1α expression abrogated the inductions at 1%, 3% and 10% O2 all 
equally efficient down to transcript parity (i.e. H/N ratios = 1.0 for siHIF-1α treatment; see Fig. 3 and 
Table 3), responses of BNIP3 to 1-10% O2 appear to rest entirely on functional HIF-1. Upon silencing of 
USF1, but surprisingly not USF2a, we observed the BNIP3 induction to be potentiated almost 
significantly at 3% O2 {3.3-fold (scr) " 4.6-fold (siUSF1); p = 0.070}, and to a significant extent at 10% 
O2 {1.6-fold (scr) " 2.2-fold (siUSF1); p = 0.019} (Table 3). This USF1 loss-of-function mediated 
enhancement resulted from the combination of reduced normoxic {1.0 (scr) " 0.7 (siUSF1)} and, 
towards milder hypoxia, progressively increasing hypoxic levels of BNIP3 transcripts {with 100% 
mRNA level (scr) " 84% - 95% - 105% mRNA level at 1% O2 - 3% O2 - 10% O2 (siUSF1)}. 
 
While we were encouraged by these early data suggesting a competitive crosstalk to occur between 
basally active HIF-1 and USF factors in cells facing a sub-normoxic milieu, the remainder of the study 
focused on providing proof-of-principle evidence for USF-mediated positive or negative functional 
interactions with HIF-1 at 1% O2. At this level of deoxygenation HIF-1 activity peaks in many cell lines, 
hence, its transcriptional control of the bulk of downstream targets is expected to operate with optimal 
efficacy. Alignments of the homologous regions of BNIP3 promoters had revealed a remarkable hmr 
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conservation around the HRE motif (Suppl. Fig. S2). For this reason we went on to compare the promoter 
responses of BNIP3, where the HRE and CACGTG motifs are contained within a single cis-element, with 
those of MC1R, 4EBP1 and LDHA genes, which all possess distinct HRE and palindrome sites of 
variable hmr conservation (Table 2; Fig. S2). Parallel chromatin immuno-precipitation (ChIP) 
experiments confirmed the recruitment of hypoxia-inducible HIF-1α- and constitutive USF1- and USF2a-
containing complexes to both LDHA (Fig. 4A) and BNIP3 (Fig. 4B) promoter sequences in intact Hep3B 
(Fig. 4, left panels), MCF7 (Fig. 4, right panels) and HeLa cells (not shown). This coordinate binding of 
HIF-1 and USFs was seen both at low oxygen (at LDHA + BNIP3 promoter) and in oxygenated nuclei as 
well (see HIF-1α at BNIP3 promoter; Fig. 4). The latter finding added weight to the notion of HIF-1 
controlling BNIP3 transcription even under sub-normoxic/normoxic conditions (see previous paragraph).  
 
To further study the convergence of HIF and USF pathways at DNA level, the promoter regions in 
question were amplified from genomic DNA, cloned, sequence confirmed and inserted into pGL3 basic 
luciferase reporter plasmids. The set of luciferase promoter reporters thus obtained included both donated 
(i.e. BNIP3 and PHD2) and self-generated constructs (TYR, 4EBP1, LDHA, MC1R), and covered USF-
specific (i.e. TYR; (43) or HIF-1 specific targets (i.e. PHD2; (44) plus four HRE/palindrome candidates 
(4EBP1, LDHA, MC1R, BNIP3; Table 2, Fig. S2). We initially examined the hypoxia (1% O2/16h) 
responsiveness of these candidate promoters. Respective reporter transfections of Hep3B, MCF7 and 
HeLa cells included negative control reactions (i.e. “bVec” = empty pGL3 basic luciferase vector; Fig. 5) 
to monitor basal and hypoxia-nonresponsive LUC activity. In contrast, the PHD2 luciferase construct was 
induced approximately 3-8-fold in hypoxic Hep3B, HeLa and MCF7 cells (Fig. 5). Luciferase assays with 
the four candidates 4EBP1, LDHA, MC1R and BNIP3 revealed only for LDHA (~2-fold) and BNIP3 (4-
7-fold) a robust up-regulation by hypoxic conditions in Hep3B, MCF7 and HeLa cells. 
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Next, we investigated the possible co-regulation of BNIP3 and LDHA reporter by HIF and USF cascades 
in co-transfections with HIF-1α and USF1, 2a or 2b expression plasmids (Fig. 6). In pilot studies (not 
shown), we had carefully titrated for each cell line the amount of HIF-1α plasmid (i.e. 15-100 ng) needed 
for an optimal hypoxic induction of either reporter and of any USF plasmid (i.e. 15 ng) needed for an 
optimal specific activation of either reporter construct (Fig. 6). The activity of the TYR promoter reporter 
rose constitutively 4-7-fold upon USF1-, and up to 20-fold upon USF2a, co-transfection. Over-expression 
of HIF-1α did not impact the TYR reporter (Fig. 6A). On the other hand, PHD2 reporter activity was 
significantly increased in normoxic and hypoxic Hep3B upon HIF-1α over-expression. The impact of over-
expressed USFs on the PHD2 reporter was either negligible (USF1) or attributed to non-specific stimulation 
by the over-expressed factor (USF2a) exerted on the vector backbone. Therefore, both control reporters 
responded specifically to the over-expression of their respective transcriptional driver(s) (Fig. 6A).  
 
The LDHA promoter was induced by endogenous hypoxia signals almost 2-fold in Hep3B (Fig. 6B), and 
additionally stimulated upon co-transfection with USF1, and particularly, USF2a and 2b plasmids. Of 
note, over-expressed USFs augmented LDHA luciferase activity predominantly under normoxia, thereby 
reducing the original hypoxic induction to an almost constitutive expression in Hep3B (Fig. 6B) and 
MCF7 cells (not shown). The switching from HIF- to USF-driven trans-activation modes, and vice versa, 
was further observed for the endogenous LDHA promoter, particularly in Hep3B (Fig. 4A, left panel) and 
HeLa cells (not shown). Here, hypoxia clearly promoted HIF-1 binding and, in parallel, attenuated the 
occupancy of USF1 and USF2a. Thus, HIF-1 and USF complexes recruited to the LDHA promoter cap 
the activity of one another to yield a pO2-dependent complementation mode of gene control.  
 
Based on these data, transactivation of the LDHA gene by HIF-1 and USFs proceeds from distinct motifs 
(below) and peaks at varying pO2 (USFs " aerobic LDHA expression; HIF-1 " hypoxic LDHA 
expression). In contrast, both pathways must converge onto a single stretch of DNA within the BNIP3 
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promoter (Suppl. Fig. S2, and below). The relevant reporter was nearly 3-fold hypoxia induced by 
endogenous HIF-1-mediated (Fig. 3) signaling in Hep3B (Fig. 6C) and HeLa cells (Fig. 6D). Co-
transfection with USF1 and 2a, or with USF2b, enhanced BNIP3 promoter activity in both cell lines 
particularly under normoxia and consequently weakened the reporters’ hypoxic induction. Over-
expression of HIF-1α amplified the hypoxic BNIP3 activity robustly in Hep3B (6.6 fold; Fig. 6C) and 
moderately in HeLa cells (3.2 fold, Fig. 6D). However, this potentiated hypoxia response of BNIP3 by 
ectopic HIF-1α was significantly impaired through the simultaneous co-transfection with USF1 or USF2a, 
but not USF2b, in Hep3B and HeLa cells (Figs. 6C+D: see $ arrows). Increasing the amount of USF1/2a 
plasmids further (15"100ng) converted the hypoxic trans-activation of the reporter into an increasingly 
constitutive response, especially in Hep3B cells (Fig. 6C). These data suggest that HIF-1α and USF1 or 
USF2a compete dose-dependently with each other over the control of the BNIP3 site. 
 
The functionality of the computed HIF-1 and USF1/2 sites in the LDHA and BNIP3 promoter was 
assessed by EMSA screens with Hep3B, HeLa and MCF7 normoxic and hypoxic nuclear extracts. 
Representative results are shown for LDHA (MCF7 nuclear extracts, Fig. 7A) and BNIP3 (Hep3B 
nuclear extracts, Fig. 7B). The wildtype CACGTG-motif in region I (Fig. S2) of the LDHA promoter was 
weakly bound by a hypoxia-regulated complex containing HIF-1α (see supershift (ss) – lane 4; Fig. 7A) 
and avidly bound by the constitutive complex (cc) factors USF1 and USF2a (see ss in lanes 6, 7 and 9, 10; 
Fig. 7A – reg.I wt). Another radiolabeled oligonucleotide, spanning the wildtype region II and III (Fig. S2: 
reg.II/III ww) was tightly bound both by HIF-1α and USF1/2 (Fig. 7A, lower panel; detection of HIF-
1α ss: lane 4; USF2 ss: 9+10). When using a reg.II/III double site oligonucleotide carrying a mutation in 
region II and an unaltered wildtype sequence in region III (reg.II/III mw), only the hypoxia inducible 
complex, supershifted by anti-HIF-1α, was detected in conjunction with a complete loss of the 
constitutive binding activity by USFs (Fig. 7A: reg. II/III mw). The reverse sequence alteration in region 
III but not II (reg. II/III wm) left the oligonucleotide attachment by the constitutive USF complex 
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undisturbed, but erased any interaction with HIF-1. Thus, the LDHA-region II acts as exclusive, high-
affinity site for USFs, while LDHA-region III attracts HIF-1 to this promoter in deoxygenated nuclei.  
 
In contrast to this segregated binding of HIF-1 and USFs in the LDHA promoter, either complex 
interacted with the -259/-236 DNA of the BNIP3 promoter containing the HRE at -251/-246 (Fig. S2) 
(Fig. 7B). Specific supershifts were able to positively identify HIF-1α (ss: lane 4) as constituent of a 
hypoxic binding activity (lane 2), and USF1 (ss: lanes 6+7) and USF2 (ss: lanes 9+10) as participants of a 
constitutive complex (cc; lanes 1+2) (Fig. 7B). We further elaborated whether the HIF-USF interplay at 
the -251/-246 core element of BNIP3 is governed by differential affinities of the respective factors. To 
that end, we conducted additional pull-down analyses using magnetic beads coated with biotinylated 
wildtype (w-bio) BNIP3 HRE probes (Suppl. Table ST1) and assessed binding specificity and avidity in 
reactions containing 10× or 50× excess of wt competitor (comp.) oligonucleotides or beads coated with 
mutant (m-bio) probes (Suppl. Fig. S3). 10× and 50× excess probe diminished the initial binding activity 
(set to 100% in each case) to a mean (n = 3-4 independent assays) residual activity of: a) ~8.8% (10×) and 
~5.4% (50×) for hypoxic HIF-1; b) ~1.3% and ~0.4% for normoxic or hypoxic USF1; and c) ~2.6% and 
~1.4% for normoxic or hypoxic USF2a, respectively. The fact that 10×/50× excess probe sufficiently 
eliminated almost all of the USF-bead interaction demonstrated the, relative to hypoxic HIF-1, much 
weaker in vitro affinity by which USF1 and 2a constitutively bind to the BNIP3 HRE (Suppl. Fig. S3). 
 
 
Discussion 
 
One way to fine-tune, or inhibit, HIF’s transcriptional outflow independently of hydroxylase activities 
could be through competing transcription factors. We reported earlier (18) that binding of a Hep3B factor 
to CACGTG motifs was able to counteract the HIF-driven induction of the phb2 reporter from HREs at 
adjacent positions. Evidently, palindrome factors can engage in positive or negative crosstalk with nearby 
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HIF/HRE complexes (45-47). En route towards a more physiological understanding of hypoxic signaling, 
we thought to analyze gene control mechanisms not just as a function of the stability/activity of HIF-1 per 
se. Rather, the dynamical interplay between transcriptional complexes that governs the hierarchy by which 
HIF-1 and related factors gain access to DNA and regulate expression was considered. The current study, 
thus, aimed to i) identify the phb2 CACGTG-binding entity in human cancer cells and ii) investigate the 
factors interplay with HIF-1 in the control of selected examples of co-targeted genes. 
 
Both, EMSA supershifts and oligonucleotide pull-down assays consistently identified USF1 and 
USF2a/2b as the main phb2 CACGTG-complex in nuclear extracts from Hep3B and HeLa (Fig. 1) or 
MCF7 cell lines. Our pull-down assays also documented the preferential in vitro docking of HIF-1 to the 
asymmetric -107 phb2 HRE and of USFs to the symmetrical -146 phb2 palindrome motif (Fig. S1B+C, 
50× comp. lanes). Thus, the single base substitution within the hexameric core of either motif (i.e. -107 
HRE: 5’-TACGTG-3’; -146 palindrome: 5’-CACGTG-3’), and presumably additional changes in 
neighbouring nucleotides, are key in conferring the vastly differing affinities of HIF and USF transcription 
factors to these motifs. This observation fits well with the general perception that CACGTG-palindromes 
tend to attract non-HIF bHLH factors (25, 36, 37, 47), and, consequentially, are notably underrepresented 
amongst functional HIF elements (48-50). Our co-immunoprecipitations further demonstrated the 
interactive precipitation of HIF-1α by ARNT proteins and vice versa but failed to reveal any physical 
contact between USF2a and either subunit of HIF-1 (HIF-1α, ARNT) (see Fig. S1D+E and (41)). Thus, 
the constitutive USF1/2a are the main factors that indirectly interfere with the HIF/HRE-driven induction 
of hb2 globin gene by binding to the phb2 CACGTG palindrome in human cancer cells (18, 31).  
 
Upstream stimulatory factors belong to the basic helix-loop-helix-leucine zipper (bHLH/ZIP) family of 
transcription factors (21, 51, 52). They can mutually influence each other’s expression, both in positive 
(USF2 trans-activates USF1 gene, (42); USF2a knockdown yields diminished USF1 levels; Fig. 2) and 
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negative ways (USF1 represses USF2 gene; USF1-/- mice show elevated USF2 levels, (42)). USFs have 
been implicated in conferring the UV-induced tanning response in melanocytes and in acting as anti-
proliferative agents in cells transformed by over-expressed MYC or activated RAS-signaling (53). 
Following a marked depletion of intracellular calcium during the differentiation of erythroid progenitor 
and erythroleukemia cells, endogenous USFs start to accumulate and trans-activate several adult marker 
genes (e.g. β globin) that ultimately drive the cells into maturity (54). Beyond MYC, palindrome 
complexes can also counteract, or interfere with, HIF’s transcriptional read-out. To date, three human 
genes have been examined as HIF/USF co-regulated targets, i.e. the genes encoding plasminogen 
activator inhibitor-1 (PAI-1) (55-57), the catalytic subunit of the telomerase, the telomerase reverse 
transcriptase (TERT) (58-60) and the glycolytic enzyme L-type pyruvate kinase (L-PK) (41). 
 
Guided by Daphnia’s phb2 coordinates we conducted a genome-wide computational survey for HIF/USF-
co-responsive human genes that were flanked by closely adjacent or over-lapping CACGTG palindrome 
and HRE motifs. Among those we found LDHA and BNIP3 to be expressed and hypoxia-induced at 
transcript level in human Hep3B cells (Fig. 3). This induction was entirely dependent (BNIP3), or aided 
(LDHA), by HIF-1α in Hep3B cells. The O2-responsive control of BNIP3 via HIF-1α ranged, in Hep3Bs` 
at least, from harsh (1% O2) to moderate (3% O2) to mild (10% O2) degrees of deoxygenation. Since the 
promoter of either gene recruited both HIF-1 and USFs in hypoxic Hep3B and MCF7 cells in vivo (Fig. 4), 
control of LDHA and BNIP3 expression was considered suitable to examine HIF/USF crosstalk at DNA 
level in greater detail. Previous studies had already validated human LDHA and BNIP3 genes as hypoxia-
inducible HIF-1 targets in HeLa and MCF7, respectively (48, 61). 
 
Luciferase reporter of the LDHA (~2-fold) and BNIP3 (3.5-7-fold) promoter yielded a robust up-
regulation by hypoxic (1% O2/16h) conditions across Hep3B, HeLa and MCF7 cells (Fig. 5). In co-
transfection assays in Hep3B cells, over-expressed USFs were found to up-regulate the LDHA reporter 
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particularly in normoxic conditions (Fig. 6B). The role of USFs’ in transactivating LDHA in oxygenated 
cells implies the factors as candidate drivers of aerobic glycolysis in cancer cells (Warburg effect). A 
previous study had already described rat LDHA as MYC target and further noticed the weak up-regulation 
of the gene by USFs under normoxia via binding of both E-box sites, reg. I and reg. II, within the rat 
LDHA promoter (62). The human LDHA promoter was, during low pO2, predominantly bound by HIF-1, 
which, in Hep3B and HeLa but not MCF7 cells, evidently served to displace LDHA-attached USFs (Fig. 
4A). Subsequent EMSA gel supershift assays revealed region I of the 5’ flank of the LDHA gene as weak 
HIF-1 and strong USF1/2a site. The region II palindrome and region III asymmetric E-box of LDHA, 
however, functioned as USF1/2 (reg. II) and HIF-1 (reg. III) binding sites, respectively (Fig. 7A). To 
rationalize these data we surmise that, in Hep3B and HeLa cells at least, the sites in regions I-III do not 
appear to be segregated. Upon changes in pO2 they rather act as adaptable platform for the dominant 
transcription factor entity. Thus, in hypoxic Hep3Bs` and HeLas`, HIF-1 might variably expand its LDHA 
occupancy from its holdout at region III onto regions I and II as well and, by doing so, displaces bound 
USFs from these regions in intact cells. At the same time, the presence of distinct, non-overlapping sites 
in the LDHA promoter forms the very foundation for the complementing control of this gene by HIF-1 
and USF pathways (Fig. 6 and 7A). This complementation allows the HIF-driven expression of LDHA 
during hypoxia to eventually switch to a USF (and MYC)-mediated control under high pO2 which, in turn, 
ensures production of this glycolytic enzyme in response to a broader O2 spectrum and additional micro-
environmental stimuli of solid malignancies (i.e. acidic milieu). 
 
Co-transfection of Hep3B and HeLa cells with HIF-1, USF1 and 2a revealed the dose-dependent 
interference with the HIF-1-mediated BNIP3 induction at 1% O2 by USFs (see   arrows, Fig. 6C and D). 
Conversely, the transient loss of USF1+USF2a functions (siUSF2a treatment, Fig. 2), or of USF1 activity 
alone (siUSF1 treatment), resulted in Hep3B cells in a significantly augmented induction of BNIP3 (and 
BNIP3L) genes at harsh (1% O2) and mild (10% O2) degrees of deoxygenation, respectively (Fig. 3; Table 
3). These data support the notion of an increasing competition of HIF`s BNIP3 control by endogenous 
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USF1 in mildly O2-deprived cells (see also below). The HRE at position -251/-246 in the promoter of 
human BNIP3 gene was first identified by Kothari and co-workers to function as a direct functional 
binding site for HIF-1 under hypoxia (61). Our EMSA screen with a single site oligonucleotide (-259/-236; 
Suppl. Table ST1) characterized this HRE-containing sequence as being co-targeted by HIF-1 and USFs 
in hypoxic (1% O2/16h) cells (Fig. 7B). Additional pull-down assays revealed hypoxic (1% O2/16h) HIF-1 
complexes to dock, in vitro, much more tightly to the BNIP3 HRE than do USF1 and 2a factors (Suppl. 
Fig. S3). Since pull-downs utilize, EMSA-like, nuclear extracts with free, DNA-dissociated alpha subunits, 
they cannot provide insights on the binding of normoxic HIF-1 to the cis-element in question. Nonetheless, 
we extrapolate a markedly inferior affinity of USFs to the BNIP3 HRE when compared to hypoxic HIF-1 
complexes under in vivo conditions as well.  
 
Although USF expression manipulations affected BNIP3 gene/reporter activity particularly in normoxia 
(i.e. note BNIP3 inductions at 1% O2 in a) Fig. 3, USF1/2a knockdown (kd): 4.8fold (scr) " 6.6-7.6fold 
(kd); b) Figs. 6c, 6d; USF1/2a overexpression: 2.8fold (endogenous) " 1.5-1.8fold (overexpression)), 
several additional observations implied the USF/HIF convergence onto BNIP3 to follow far more 
intricate rules than a LDHA-like segregation between normoxic/USF and hypoxic/HIF occupations would 
suggest. Firstly, ChIP analysis of all three cell lines (Hep3B, MCF7, HeLa) showed measurable amounts 
of HIF-1 during normoxia, and of USF1/2 complexes during normoxia and hypoxia, attached to the 
BNIP3 promoter chromatin (Fig. 4 and data not shown). Secondly, the USF1/2 dimers, tethered to the 
same -251/-246 core sequence as the hypoxia-inducible factor during low pO2 (Fig. 7B), showed virtually 
no signs of displacement by incoming HIF-1 (Fig. 4). Such a persisting attachment of USF factors during 
hypoxic periods of HIF-1 occupancy could be achieved by the presence of secondary docking sites within 
the BNIP3 promoter. Indeed we noted hmr conserved CACGCR motifs dubbed E1 and E2, separated by 
3-nucleotide spacers on either side of the -251/-246 BNIP3 HRE (i.e. 5´ CACGCGccgCACGTGcca 
CACGCA 3´; E1/E2 = capital; spacers = small; HRE = capital/bold; see Table 2; Suppl. Fig. S2). 
Subsequent EMSA experiments using triple site E1-HRE-E2 oligonucleotide probes in www (all three 
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sites intact) and mwm (HRE intact, E1+E2 mutated) configuration revealed for hypoxic extracts (HIF-1 
docked to HRE) a 1.3-2.3 fold stronger binding of USF complexes to www than mwm sequences (not 
shown). Thus, intact E1/E2 motifs (and several other CACGCN promoter sites) can temporarily provide 
alternative USFs sites at the BNIP3 gene. When HIF-1 approaches the BNIP3 HRE during low pO2 in 
vivo, USFs may be able to sidestep displacement by sliding onto E1 and E2. 
 
The fact that we detected HIF-1α tethered to the BNIP3 promoter in normoxia only in vivo (ChIP), but 
not by in vitro (EMSA, pull-down) measures, may highlight the protective effect of chromatin and/or the 
required HIF-1 heterodimer under conditions where free alpha subunits are all but depleted due to 
ongoing hydroxylation and degradation. Since none of the usual pro-inflammatory agents (e.g. cytokines, 
growth factors, reactive oxygen species), known to spark a strong non-hypoxic HIF-1α accumulation 
and induced expression of HIF-1 targets, were added to our cultures the select interaction of HIF-1 with 
the BNIP3 promoter in oxic cells appears to occur independently of changes in cytokine/growth 
factor/ROS concentrations. Regarding the question whether DNA-bound HIF-1 in oxic cells maintains 
transcriptional functionality, we found that, in Hep3B cells subjected to 16h periods of 3% and 10% O2, 
HIF-1α still manages to drive the induction of BNIP3 (Table 3). Overall, however, our knowledge is 
meager at best when it comes to events emanating from HIF-signaling in mildly deoxygenated or 
completely aerobic cells. A noted exception is a study by Welford and colleagues which documented 
HIF-1 to be strictly necessary in delaying the onset of cellular senescence in aerobic murine embryonic 
fibroblasts, in part via the transcriptional control of the pro-inflammatory macrophage migration 
inhibitory factor (MIF) (63).  
 
Taken together, the distinct sites of the LDHA promoter allow switching between USF/normoxic and 
HIF-1/hypoxic states, in favor of a complementing expression profile with a broadened O2 sensitivity. In 
contrast, the single BNIP3 sequence around the -251/-246 CACGTG motif seems to be the platform for a 
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pO2-dependent, conditional competition between USF1/2a and HIF-1 (i.e. a) normoxic/sub-normoxic 
state: USF1 HIF-1; b) hypoxic (1% O2) state: HIF-1 only; with 1  = competition). If so, this conditional 
competition would argue for different DNA-affinities and/or transactivation competences of normoxic 
and hypoxic HIF-1 complexes, respectively. Inadequate α:β subunit-interactions, however, are unlikely to 
be involved in debilitating affinity or transcriptional capacity of normoxic HIFs (relative to species at 1% 
O2). Recent fluorescence resonance energy transfer measurements revealed, at least for proteolysis-
saturating levels of over-expressed HIF-2α and ARNT, identical α:β distances in normoxic and hypoxic 
HIF-2 heterodimers (64). While the assembly of HIF in oxygenated and severely hypoxic nuclei appears 
to match one another, the α-subunits in such high-pO2, HRE-tethered dimers should show hydroxylation 
at ODD-prolyl and/or CAD-asparaginyl residues. 
 
The recent categorization of HIF-1 targets into PHD- (driven by HIF-1α NAD activity) and PHD/FIH-
dependent cohorts (driven by HIF-1α NAD + CAD activity) has yielded some surprising new insights 
regarding the O2-profiles of LDHA and BNIP3 genes (15-17). Here, BNIP3 expression was characterized 
by extremely low FIH-1 sensitivity scores, indicating full responsiveness of the gene by marginal drops of 
pO2 and transcriptional gene induction (rather than inhibition) by active FIH-1. In line with this concept, 
we find BNIP3 to be induced via HIF-1α in hepatoma cells at 1%, 3% and 10% O2 (Fig. 3, Table 3). 
While possible functions of BNIP3, in addition to the factors pro-apoptotic/pro-autophagic dichotomy (65, 
66), need to be clarified for mildly versus profoundly hypoxic cancer cells, the binding of HIF-1 to the 
BNIP3 promoter under a wide range of pO2, and to the LDHA sites selectively during hypoxia, agrees 
with such non-redundant impacts of PHDs and FIH-1 on the activity of these HIF targets. In USF-1 
silenced Hep3B, BNIP3 mRNA expression levels were, relative to controls transfected with scrambled 
RNA, reduced in normoxic cells and steadily increasing in cells experiencing ever milder degrees of 
hypoxia. This mix of effects yielded, as result of the USF1 knockdown, a progressive potentiation of the 
BNIP3 induction from harsh (1% O2) to moderately (3% O2) to mildly (10% O2) deoxygenated Hep3Bs 
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(Fig. 3, Table 3). We therefore surmise that endogenous USFs primarily cap the activity of the HIF-
1/HRE complex at BNIP3 during normoxia-mild hypoxia; i.e. interfere with HIF-1 complexes whose 
alpha subunits remain either fully (i.e. at ODD/NAD + CAD) or partially (i.e. at CAD) hydroxylated. The 
HIF-1/HRE complex under strictly hypoxic (1% O2) conditions, i.e. with complete dehydroxylation of 
alpha subunits at NAD and CAD regions, is, however, due to HIF´s superior DNA affinity dominant over 
endogenous USFs. Now, upstream stimulatory factors will only through over-expression still be able to 
shift the binding equilibrium to the BNIP3 HRE in their favor and guard the site against HIF-1. Thus, 
USF1 and 2a are best viewed as pO2-dependent conditional, not compulsory, HIF-interfering factors. 
Their delimiting impact on hypoxic signaling likely occurs most effectively towards HIF’s temporal or 
O2-limits (i.e. during anoxia or re-oxygenation), or in response to a strong physiological activation of the 
USF pathway (i.e. i) UV-induced USF1 phosphorylation in cells of melanocytic origin (53); ii) Ca2+-
depletion based protection from proteolysis in differentiating erythroid progenitor/erythroleukemia cells 
(54)). Future work should tap into genome-wide implications of co-activated cross talk between 
endogenous USFs and HIF-1 in appropriate models. 
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Legends 
 
Table 1. Top 10 pathways enriched with HRE/CACGTG-genes. Pathways with the most significant 
overrepresentation of HRE/CACGTG-genes are listed with their GeneGo Name, a brief description and a 
p-value indicating the significance of the overrepresentation of HRE/CACGTG-genes. The Network 
Objects column gives the number of network objects of the pathway encoded by HRE/CACGTG-genes 
over the total number of network objects in the pathway. The last column shows the gene symbols of the 
HRE/CACGTG-genes in the pathways. Bold Gene Symbols denote multiple HRE-CACGTG signatures 
flanking the gene, while Symbols in normal font contain one HRE-CACGTG signature in their promoter. 
A more detailed description of these HRE-CACGTG gene candidates can be found in the gene Excel list 
available upon request. 
 
Table 2. E-box palindromes and HRE sites in promoters of human genes. HIF-1 and USF co-
regulated candidate genes: 4EBP1, LDHA, MC1R and BNIP3; control genes: TYR and PHD2. 
Translation start site ATG as +1 (in brackets). 5’ flanking region upstream of ATG is given for human 
TYR, PHD2, 4EBP1, LDHA, MC1R and BNIP3 genes. HRE and E-box palindromes are capitalized. 
Human-mouse-rat (hmr) conserved HREs: bold + underlined; variable HREs: bold only; hmr conserved 
E-boxes: italicized + underlined; variable E-box: italics only. For conservation: see alignments in Fig. S2. 
 
Table 3. BNIP3 mRNA fold inductions in mildly deoxygenated Hep3B transfected with siRNAs. 
Hep3B transfections with scrambled (scr) control RNA or HIF-1α, USF1 or USF2a siRNA followed the 
identical protocol used for the quantitative expression analyses in Fig. 3 (see there). BNIP3 mRNA levels 
were quantified by real-time PCR and normalized by L28 expression. Fold inductions of BNIP3 transcript 
levels in mildly deoxygenated (H: 3% or 10% O2; 16h) versus normoxic (N: air; 16h) Hep3B are given as 
means (± SD) of three independent experiments. P-values for H/N-fold changes between siRNA-treated 
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experimental groups (i.e. siX = siHIF-1α or siUSF1 or siUSF2a) and the scr control group of the same O2 
category (i.e. comparison done only within 3% or 10% O2 category) are indicated. 
 
Fig. 1. EMSA supershifts and pull–down analysis to identify phb2-binding CACGTG complex in 
Hep3B cells. (A) To identify factor(s) able to bind to the -146 CACGTG motif in phb2, we used the 
following antibodies in EMSA supershift reactions with Hep3B normoxic nuclear extracts as indicated in 
the figure underneath each lane. (-): no antibody; PI: pre-immune serum; ns: non-specific; cc: constitutive 
CACGTG complex; ss: supershifted CACGTG complex. From lane 4-13, EMSA reactions were 
supplemented by corresponding pre-immune (PI) and immune serum from the same rabbit used to 
generate anti-USF directed antibodies (e.g. lanes 4+5: PI-1M and anti-USF1M). Results reproduced in n = 
3 independent assays. (B+C) Pull-down analysis with beads coated with -146 phb2 E-box-carrying 
oligonucleotides (5’-CACGTG-3’) and HeLa normoxic (N) and hypoxic (H) nuclear extracts. Binding 
specificity was assessed either through beads coated with -146 mutant (m-bio) E-box motifs (5’-
CAATGT-3’) or with binding reactions containing 50-fold molar excess of free wild type oligonucleotide 
as competitor (50×comp.). Immunoblot of bound factors with (B) α-USF1M and (C) left panel: α-USF2G 
antibody; right panel: α-USF2aO antibody. Staining of non-specific (ns) proteins indicated as loading 
control. Results reproduced in n = 3-4 independent assays. 
 
Fig. 2. Western blot analysis for transient siRNA knockdown efficiency for HIF-1α , USF1 and 
USF2a in Hep3B cells. Transfections with scrambled siRNA (scr) and non-transfected cells (non-TF) 
were used as negative controls. Cells were harvested at two post-siRNA transfection time points: 48h and 
72h. Hypoxia (H, 1% O2) exposure started at time point 42h post-siRNA transfection for 6h and 30h, 
respectively. Normoxia (N): air exposure. As shown in the figure, protein level expression of HIF-1α and 
each USF in transiently transfected Hep3B cells was robustly silenced from 48h (= 42h + 6h hypoxia) up 
to 72h (= 42h + 30h hypoxia) post-siRNA transfection. 
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Fig. 3. Real-time quantitative PCR for (top left – bottom right) BNIP3, BNIP3L, LDHA, 4EBP1 and 
VEGFC mRNA levels in Hep3B transfected with siRNAs. Hep3B cells were transfected with HIF-1α, 
USF1 or USF2a siRNA at a final concentration of 200nM. Scrambled siRNA (scr) was used as negative 
control. RNA was isolated from Hep3B at 66h post-siRNA transfection, i.e. at a time point where the 
silencing effect of HIF-1α and USFs was still in effect (see Fig. 2). Hypoxia (1% O2) exposure started at 
time point 50h post-siRNA transfection for 16h. Normoxia (N): air exposure. mRNA levels of above 
named genes were quantified by real-time PCR and normalized by L28 expression. All data were 
presented as the means ± SD of four independent experiments. N: air; H: 1% O2 16h. Mean H/N-fold 
inductions of each transcript are indicated above the respective pair of columns. Mean expression of 
individual transcripts were compared a) within same O2 category (N or H), and b) for H/N-fold changes 
of siRNA-treated experimental groups (siHIF-1α, siUSF1, siUSF2a) relative to scr controls. For these 
scr/si-comparisons, the used symbol denotes pairwise non-parametric Wilcoxon rank-sum tests (#). See 
Materials and Methods for more details. 
 
Fig. 4. Chromatin immunoprecipitation (ChIP) determination of in vivo HIF-1 and USF binding to 
LDHA and BNIP3 promoters. ChIP assay was performed in Hep3B (left panels) and MCF7 (right 
panels) cells using indicated antibodies or pre-immune serum and non-specific antibody IgG as negative 
controls. Purified DNA was subjected to PCR using LDHA primer (panel A: 159 bp amplicon) or BNIP3 
primer (panel B: 314 bp amplicon). N: air; H: 1% O2 4 h. PI-2G pre-immune serum for anti-USF2G; neg. 
PCR with H2O. 
 
Fig. 5. Endogenous response of PHD2, 4EBP1, LDHA, MC1R and BNIP3 luciferase reporter. 
Hep3B (A), MCF7 (B) and HeLa (C) cells were transfected with 2.0µg of 4EBP1, LDHA and MC1R or 
1.5µg of PHD2 or BNIP3 luciferase reporter plasmid in a total of 3.0µg plasmid. After 16h hypoxic (1% 
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O2) exposure (H, black bars) or normoxic (air) exposure (N, white bars), relative luciferase activity was 
determined and normalized with β–galactosidase activity (%RLA, as mean ± SD). Plasmid-free 
transfections (null) and transfections with the empty pGL3 basic vector (bVec) were used as negative 
controls. Mean H/N-fold inductions of each reporter are indicated above the respective pair of columns.  
 
Fig. 6. Regulation of BNIP3 and LDHA luciferase activity by over-expressed HIF-1α  and USFs. (A) 
Hep3B transfections of USF and HIF-1 control reporter using either 1.5µg TYR plasmid or 0.5µg PHD2 
plasmid. (B) Hep3B transfections with 0.3µg LDHA reporter plasmid. (C) Hep3B or (D) HeLa 
transfections with 0.3µg BNIP3 reporter plasmid. For reporter regulation by over-expressed HIF-1α and 
USFs, ng amounts of HIF-1α and USF expression plasmids used are indicated underneath the respective 
co-transfection. Relative luciferase activity is given as in Fig. 5 (mean ± SD %RLA; n = 3 independent 
experiments). N, H conditions and presentation of mean H/N-fold inductions as in Fig. 3. Statistics done 
in regard to same O2 category (i.e. N or H): a) endo/exo test = endogenous controls (reporter alone; no 
over-expressed HIF/USF) versus HIF/USF co-transfection (reporter with exogenous HIF-1α and/or 
USF1/2a); b) hif/combi test: reporter + exogenous HIF1α versus reporter + exogenous (HIF1α + 
USF1/2a). Symbols for p < 0.05 for i) non-parametric Wilcoxon rank-sum tests (endo/exo = #; hif/combi 
= ¶); ii) Anova/Sidak tests (endo/exo = ∗ ; hif/combi = +). See Material & Methods for more details. 
 
Fig. 7. EMSA supershifts with LDHA and BNIP3 E-box oligonucleotides. Gel supershift using LDHA 
HRE and E-box palindrome oligonucleotides together with MCF7 nuclear extracts (panel A) and BNIP3 
HRE oligonucleotides together with Hep3B nuclear extracts (panel B). All oligonucleotides used in this 
EMSA are listed in Table ST1. For HIF-1α or USFs gel supershifts, 1µl of the indicated specific antibody 
was used in comparison with pre-immune serum (PI-1M or PI-2G) or non-specific lgG as negative 
control. N, H, cc, ss: as above. 
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Table 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Sequence 5’-3’ Ref. 
 
hTYR 
          -183   -178                  -91   -86 
gaaaagtcagtCATGTGcttttca---gccaagaCATGTGataat---aggaaga(atg)  
 
(67) 
 
hPHD2 
        -413  -408 
gccgtggtgTACGTGcagagcgcgcagagcgagt---gccgccgccgcc(atg)  
 
(28) 
 
h4EBP1 
        -179  -174                   -120   -115 
ggggatccCACGTGgaagc--caaatcccaggGGCGTGgggcgg--gagacc(atg)  
 
 
 
hLDHA 
     -2465 -2460           -2367 -2362     -2353   -2348 
cagcgCACGTGgagcg--actcaCACGTGggttcccgCACGTCcgccggc--aat(atg)  
 
(62, 
68) 
 
hMC1R 
      -742   -737                 -461  -456 
acgttgaCAGCTGagttgctg--ccccggCATGTGgccgccct--ggacaggact(atg) 
 
(67) 
 
hBNIP3 
             -251  -246 
cgcgcacgcgccgCACGTGccacacgcacccca---gccctctggcgcc(atg) 
 
(61) 
 3 
Table 3 
	  
 scr siHIF-1α siUSF1 siUSF2a 
O2     
     
3% 3.325 ± 0.754 1.078 ± 0.148 4.583 ± 0.472 4.222 ± 0.907 
p (siX - vs scr) - p = 0.0072 p = 0.0704 ns 
     
10% 1.622 ± 0.177 1.055 ± 0.038 2.145 ± 0.159 1.560 ± 0.313 
p (siX - vs scr) - p = 0.0056 p = 0.0189 ns 
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Supplement Table ST1: PCR primers and oligonucleotides 
 
 
PCR primers for generation of luciferase constructs (Fig. 5, 6) 
Name For Rev 
4EBP1 F1: 5’-GTTGGTTCACTCCTCCTC-3’ 
F2: 5’-AGCATAACTACTCAATCCCC-3’ 
R1: 5’-CCAACAGATAATACCCATCC-3’ 
R2: 5’-CGTGTTTGTTAGGTGTCAG-3’ 
MC1R F1: 5’-CTGAAAACACCAACCTCTCC-3’ 
F2: 5’-CTTTCACGCTCTGCCC-3’ 
R1: 5’-CCACACAATATCACCACCTC-3’ 
R2: 5’-CACAGCCATAGTCCTGTCC-3’ 
LDHA F1: 5’-GAGTGGGAGCTGGTAGG-3’ 
F2: 5’-CAGGGATGAAGAAGAAACAG-3’ 
R1: 5’-GCTATCCAAGGCACAGG-3’ 
R2: 5’-TGAGATTTGAGTGGGAGAAC-3’ 
TYR F1: 5’-TTGTAGCCTCTTTATGGTCTC-3’ 
F2: 5´CTCTATTCCTGACACTACCTCTC 3’ 
R1: 5’-TTATTTCCCAAACATTCCTG-3’ 
R2: 5’-CCAATTAGTCTGGGATAAGG-3’ 
pCRII F1: 5’-CACACAGGAAACAGCTATGAC-3’  
LDHA/pCRII  R1: 5’-GATAAGCTTTAGAGGATGGGGTCAAGG-3’ 
Oligonucleotide sequences used for EMSA and pull-down experiments (Fig. 1, 7) Binding motifs, HREs or E-box, are underlined + in bold; h = human 
Name Sense Antisense 
Daphnia phb2 w-146HRE 5’-GAACCATACACGTGCCTCGAGCAG-3’ 5’-CTGCTCGAGGCACGTGTATGGTTC-3’ 
Daphnia phb2 m-146HRE 5’-GAACCATACAATGTCCTCGAGCAG-3´ 5’-CTGCTCGAGGACATTGTATGGTTC-3’ 
Daphnia phb2 w-107HRE 5’-ACACGGCCTACGTGATGATAGCGC-3’ 5’-GCGCTATCATCACGTAGGCCGTGT-3’ 
Daphnia phb2 m-107HRE 5’-ACACGGCCTAATGTATGATAGCGC-3’ 5’-GCGCTATCATACATTAGGCCGTGT-3’ 
hBNIP3 HRE wt 5’-ACGCGCCGCACGTGCCACACGCAC-3’ 5’-GTGCGTGTGGCACGTGCGGCGCGT-3’ 
hBNIP3 HRE mut 5’-ACGCGCCGCAATGTCCACACGCAC-3’ 5’-GTGCGTGTGGACATTGCGGCGCGT-3’ 
hLDHA reg.I wt 5’-TCCCAGCGCACGTGGAGCAGTCTG-3’ 5’-CAGACTGCTCCACGTGCGCTGGGA-3’ 
hLDHA reg.I mut 5’-TCCCAGCGCAATGTGAGCAGTCTG-3’ 5’-CAGACTGCTCACATTGCGCTGGGA-3’ 
hLDHA reg.II/III ww 5’-CGACTCACACGTGGGTTCCCGCACGTCCGCCGGC-3’ 5’-GCCGGCGGACGTGCGGGAACCCACGTGTGAGTCG-3’ 
hLDHA reg.II/III mw 5’-CGACTCACAATGTGGTTCCCGCACGTCCGCCGGC-3’ 5’-GCCGGCGGACGTGCGGGAACCACATTGTGAGTCG-3’ 
hLDHA reg.II/III wm 5’-CGACTCACACGTGGGTTCCCGACATTCCGCCGGC-3’ 5’-GCCGGCGGAATGTCGGGAACCCACGTGTGAGTCG-3’ 
hLDHA reg.II/III mm 5’-CGACTCACAATGTGGTTCCCGACATTCCGCCGGC-3’ 5’-GCCGGCGGAATGTCGGGAACCACATTGTGAGTCG-3’ 
Primers for chromatin immunoprecipitation (ChIP) (Fig. 4) 
Name For Rev 
LDHA 5’-ACTCAGGCTCATGGCTC-3’ 5’-GGCTGGGGGTGGATG-3’ 
BNIP3 HRE 5’-TAGCCAGTGCCCAGAGAGTCC-3’ 5’-ATTGGCCGCGACTTGGG-3’ 
siRNA oligonucleotides for transient knockdown HIF-1α , USF1 and USF2a in Hep3B cells (Fig. 2, 3) 
Gene Sense Antisense Genbank  accession No. Targeted region  
HIF-1 5’-CUGAUGACCAGCAACUUGAdTdT-3’ 5’-UCAAGUUGCUGGUCAUCAGdTdT-3’ AF304431.1 1380-1400 
USF1 5’-GACCCAACCAGUGUGGCUAdTdT-3’ 5’-UAGCCACACUGGUUGGGUCdTdT-3’ NM_007122 79-97 
USF2a 5’-UCCAGACUGUAACGCAGACAAdTdT-3’ 5’-UUGUCUGCGUUAACAGUCUGGAdTdT-3’ NM_003367 786-806 
Primers for real-time quantitative PCR (qPCR) of following human transcripts (Fig. 3) 
Name For Rev 
LDHA F2: 5’-GGAGATTCCAGTGTGCCTGT-3’ R2: 5’-GTCCAATAGCCCAGGATGTG-3’ 
BNIP3 F2: 5’-AGGGCTCCTGGGTAGAACTG-3’ R2: 5’-CCCTGTTGGTATCTTGTGGTG-3’ 
BNIP3L F2: 5’-GGCAATGGGAAAAATGGG-3’ R2: 5’-TCAAAGCCTCGACTTCCTTC-3’ 
4E-Bp1 F2: 5’-CGGGGACTACAGCACGAC-3’ R2: 5’-CCGCTTATCTTCTGGGCTATT-3’ 
VEGFC F4: 5’-AAACAAGGAGCTGGATGAAGAG-3’ R4: 5’-GGATTTAGGGGTTGATTTCTGG-3’ 
L28 F1: 5’-GCAATTCCTTCCGCTACAAC-3’ R1: 5’-TGTTCTTGCGGATCATGTGT-3’ 
 3 
Fig. S1: USFs bind preferentially to the -146 palindrome and HIF-1 to the -107 HRE of 
Daphnia’s hb2 promoter  
 
Additional evidence for the interaction of USFs with the -146 phb2 CACGTG palindrome was 
obtained by adding increasing volumes of anti-USF1M (left) and anti-USF2G (right) antiserum into 
the binding reaction with nuclear extracts from normoxic (N) and hypoxic (H) Hep3B cells. The 
intensity of the constitutive CACGTG complex (cc) was observed to be reduced in a dose-dependent 
manner. In contrast, addition of the maximal volume of pre-immune serum (PI-1M and PI-2G) left the 
complex’s intensity unaffected. As can be seen, binding of USF complexes to the -146 phb2 E-box is 
oxygen-independent (Fig. S1A). An earlier work had established the following isoform-specificity of 
each of the anti-USF antisera used: anti-USF1M serum recognizes USF1 (domain M), anti-USF2G 
recognizes USF2a or 2b (domain G) and anti-USF2aO recognizes USF2a (domain O) (1). Equipped 
with this knowledge, we were able in additional supershift experiments (not shown) to delineate the 
slightly different mobility of bands within the CACGTG-bound constitutive complex (Fig. S1A; cc) as 
summarized here: USF1/2 heterodimers (i.e. USF1/2a, USF1/2b, fast complex, “1/2”), 1/1 
homodimers (medium complex, “1/1”) or 2/2 homodimers (slow complex, “2/2”) (Fig. S1A; see also 
(1)). 
 
Our initial report on the regulation of Daphnia globin gene 2 (hb2) had shown that the asymmetric 
TACGTG elements at positions -258 and -107 of the promoter were absolutely necessary for the 
hypoxic induction of the hb2 gene (2). To test whether these two sites indeed comprise avid HIF 
binding sequences (i.e. are HREs), we applied the pull-down assay with beads coated either with 
wildtype -107 HRE or -146 E-box oligonucleotides for a relative comparison of HIF’s in vitro binding 
affinity. As can be seen in Fig. S1B, the amount of pulled HIF-1α protein left attached to the beads in 
the competed reactions (50× comp.) clearly demonstrates HIF’s hypoxia-induced, high-affinity 
interaction with the -107 HRE and low-affinity interaction with the -146 palindromic E-box. In 
contrast, USFs display opposite in vitro binding behavior, with a tight interaction of USF2a and 2b to 
the -146 E-box and a weak, easily competed one to the -107 HRE (note 50x comp. lanes in Fig. S1C). 
 4 
The pull-down assay thus demonstrates the opposite binding preferences of USF1/2 (primarily to 
CACGTG motif) versus HIF-1 complexes (primarily to TACGTG HRE) within the phb2 DNA in 
confirmation of our previous observations (2). 
 
To assess whether the observed (2) USF-HIF interference in phb2 results from a direct or indirect 
contact between these transcription complexes, we conducted bidirectional co-immunoprecipitation 
(Co-IP) experiments. Positive Co-IP controls clearly confirmed precipitation (IP lanes), hence physical 
contact, between HIF-1α with immobilized ARNT (Fig. S1D), or conversely, ARNT with 
immobilized HIF-1α upon the subunits accumulation in hypoxic (H) extracts (Fig. S1E). As expected, 
the minuscule amount of HIF-1α present in normoxic (N) extracts is reflected by a small quantity of 
pulled ARNT protein (Fig. S1E left). However, neither immobilization scheme for the HIF-1α or HIF-
1β (ARNT) subunit resulted in any detectable precipitation of USF2a (Fig. S1D and E right). Lack of 
co-immunoprecipitation suggests the absence of any physical interaction between HIF-1α or ARNT 
with USFs. Rather, the USF-HIF interference seems to be DNA context dependent. 
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Suppl. Fig. S1. Protein-DNA and protein-protein interactions in the phb2 promoter (A) Dose 
dependent gel supershift with normoxic and hypoxic nuclear extracts from Hep3B cells by applying 
increasing volume of anti-USF1M or USF2G IgGs into the binding reaction as indicated. 
Representative PIs were used as negative controls. cc: constitutive CACGTG complex; ss: 
supershifted CACGTG complex. (B and C) Pull-down analysis either with -107 HRE wild type 
oligonucleotides (-107 HRE: 5’-TACGTG-3’) or with -146 E-box wild type biotinylated 
oligonucleotides (-146 E-box: 5’-CACGTG-3’) using HeLa normoxic and hypoxic nuclear protein. (B) 
HIF-1α detection with anti-HIF-1α antibody (mgc3); (C) USF2a/2b detection with anti-USF2G 
antibody. Staining of non-specific (ns) proteins indicated as loading control. (D) HIF-1α (left) or 
USF2a (right): Western blot of extracts immunoprecipitated (IP) by anti mouse ARNT IgG compared 
to non-precipitated supernatants (SN). (E) ARNT (left) or USF2a (right): Western blot of extracts 
imunoprecipitated (IP) by anti HIF-1α IgG compared to non-precipitated supernatants (SN). Input: 
only nuclear extract (25µg); SN: supernatant from IP; IP: immunoprecipitation fraction, N: normoxia 
(air); H: hypoxia, 1% O2 16h. 
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Supplement Fig. S2: Human genes selected for HIF or USF control and HIF/USF co-targeted 
reporter constructs 
 
Sequence analysis (see text, Table 2) and promoter alignment revealed human-mouse-rat (hmr) 
conservation of HREs and/or E-box palindromes in the promoters of the following control (a+b) and 
HRE/E-box candidate genes (c-f) Alignment examples are presented here only for TYR, PHD2, 
LDHA and BNIP3 promoter regions (Fig. S3):  
 
a) human tyrosinase (TYR): USF specific target gene with two hmr conserved CATGTG E-boxes (-
183/-178 and -91/-86). E-box (-183/-178) validated as direct binding site for USF1 (3).  
 
b) human prolyl hydroxylase domain 2 (PHD2): HIF-1 specific target gene with hm conserved HRE (-
413/-408) as functional HIF-1 binding site (4). 
 
c) human 4E-binding protein 1 (4EBP1): contains hmr conserved E-box palindrome (-179/-174) and 
non-conserved HRE candidate (-123/-115). 
 
d) human lactate dehydrogenase A (LDHA): contains distinct, hmr conserved CACGTG palindrome 
(region II -2367/-2362) and CACGTC site (region III -2353/-2348; reads as reverse-complement: 
GACGTG) as well as another CACGTG E-box (region I -2465/-2460) with hm conservation. 
Region I and II: validated MYC binding sites (5). Region II and III: validated in vitro HIF-1 
binding sites (6). 
 
e) human melanocorticotropin 1 receptor (MC1R): contains two E-boxes, one of which with hm 
conservation (-461/-456) whose role in controlling MC1R expression in response to UVB 
(80mJ/cm2) is known thanks to the work of Corre et al. (3) .  
 
 8 
f) human BCL2/E1B 19 kDa interacting protein 3 (BNIP3): contains hmr conserved HRE (-251/-246), 
a validated functional HIF-1 site (7), which is identical to E-box palindrome. 
 
 
 
 
Suppl. Fig. S2 Mouse-rat-human alignments of relevant HRE, E-box palindrome or HRE/E-box 
containing promoter regions for genes TYR, PHD2, LDHA and BNIP3. TYR with two hmr 
conserved CATGTG E-boxes (italics + underlined). PHD2 with known functional HRE (underlined). 
LDHA with known functional HRE (underlined) and E-box palindromes (italics + underlined). BNIP3 
with known functional HRE (underlined). 
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Suppl. Fig.  S3: Pull-down analysis with human BNIP3 biotinylated wildtype -251/-246 HRE 
oligonucleotide using Hep3B normoxic (N) and hypoxic (H) nuclear extracts. Binding specificity 
was assessed either through beads coated with mutant (m-bio) HRE (5’-CAATGT-3’) or with binding 
reactions containing 10- or 50-fold molar excess of free wildtype oligonucleotide as competitor 
(comp.). Oligonucleotide sequences: see Suppl Table ST1 (hBNIP3 HRE wt, hBNIP3 HRE mut). 
Immunoblots of bound factors were performed with mouse anti-HIF1α (upper panel); anti-USF1 (C-
20) (middle panel) and anti-USF2G (lower panel). Results reproduced in n = 3-4 independent assays. 
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